Chugai Pharmaceutical Co., Ltd. (4519.T)
Key Executives
| Name | Title | Pay | Exercised | Year Born |
|---|---|---|---|---|
| Dr. Osamu Okuda | President, CEO & Chairman | 282M | -- | 1963 |
| Mr. Iwaaki Taniguchi | Executive VP, Head of Finance Supervisory Division, CFO & Director | -- | -- | 1966 |
| Toshiya Sasai | Executive of Investor Relations Group & Corporate Communications Department | -- | -- | -- |
| Junichi Takano | Head of Marketing & Sales Division | -- | -- | -- |
| Mr. Shinji Hidaka | Executive Vice President | -- | -- | -- |
| Katsuhiro Hara | Strategic Leader | -- | -- | -- |
| Dr. Takaki Koga | Polivy Lifecycle Leader | -- | -- | -- |
| Hideto Kodaira | Evrysdi Lifecycle Leader | -- | -- | -- |
| Dr. Shinta Kobayashi | DONQ52 Global Project Leader | -- | -- | -- |
| Takei Kake | GYM329 Global Project Leader | -- | -- | -- |
Chugai Pharmaceutical Co., Ltd.
- Sector:
- Healthcare
- Industry: Drug Manufacturers - General
- Full Time Employees:
- 5,026
Description
Chugai Pharmaceutical Co., Ltd., together with its subsidiaries, engages in the research, development, manufacture, sale, importation, and exportation of pharmaceuticals in Japan and internationally. It offers oncology products, such as Alecensa, Avastin, FoundationOne, Herceptin, Kadcyla, Perjeta, Polivy, Tecentriq, and Phesgo; Actemra for humanized anti-human IL-6 receptor monoclonal antibody; CellCept for immunosuppressant; Edirol, an osteoporosis agent; Enspryng, a pH-dependent binding humanized anti-IL-6 receptor monoclonal antibody; Evrysdi for spinal muscular atrophy agent; Hemlibra, an anti-coagulation factor IXa/X humanized bispecific monoclonal antibody; Mircera, an erythropoiesis-stimulating agent; PiaSky, a pH-dependent binding humanized anti-complement (C5) monoclonal antibody; Ronapreve, an anti-SARS-CoV-2 monoclonal antibody; Tamiflu, an anti-influenza agent; and Vabysmo, an anti VEGF/anti Ang-2 bispecific antibody. The company has strategic alliances and collaboration with Roche Group; and research collaboration and option to license agreement with Araris Biotech AG to develop ADCs using Araris AraLinQ technology. The company was founded in 1925 and is headquartered in Chuo-ku, Japan. Chugai Pharmaceutical Co., Ltd. operates as a subsidiary of Roche Holding Ltd.
Corporate Governance
Upcoming Events
April 24, 2025 at 8:00 AM UTC
Chugai Pharmaceutical Co., Ltd. Earnings Date
June 27, 2025 at 12:00 AM UTC
Ex-Dividend Date
Recent Events
Recent Events Information Not Available